Myrexis, Inc. (MYRX): Market cap of $106.45M. Current cash holdings at $114.27M vs. average quarterly operating expenses over the last four quarters at $10.37M. Cash/Avg. Quarterly Operating Expense at 11.02, i.e. the company can pay 11.02 quarters worth of average quarterly operating expenses without needing to generate revenue.
Yes, great cash, which is exactly why I and all the real stockholders (read not twelvetooth and jacosa) bought this. However management (Hobden particularly) have been inept and have accomplished absolutely nothing but spend that cash. To their credit they have reduced the burn rate through layoffs, however that is a bitter pill for the company morale. There seems to be no progression to an approved drug. They apparently can't even establish dosing. The best bet at this time (as well as in the past) is for them to sell the pipeline and distribute the cash to shareholders. They have negative credibility (as proven by the price to book)